Mar 27, 2024 at 10:00 AM EDT
Cara Therapeutics
Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. We are developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica, a common, underdiagnosed neuropathy affecting the upper back. We are conducting a Phase 2/3 program with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Latest Quarterly Earnings
Events & Presentations
Apr 9, 2024 at 8:40 AM EDT
Mar 27, 2024 at 10:00 AM EDT